Searched for: in-biosketch:true
person:snudem01
Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas
Richardson, Timothy E; Sathe, Adwait Amod; Xing, Chao; Mirchia, Kanish; Viapiano, Mariano S; Snuderl, Matija; Abdullah, Kalil G; Hatanpaa, Kimmo J; Walker, Jamie M
Chromosomal instability due to mutations in genes guarding the stability of the genome is a well-known mechanism underlying tumorigenesis and malignant progression in numerous cancers. The effect of this process in gliomas is mostly unknown with relatively little research examining the effects of chromosomal instability on patient outcome and therapeutic efficacy, although studies have shown that overall/total copy number variation (CNV) is elevated in higher histologic grades and in cases with more rapid progression and shorter patient survival. Herein, we examine a 70-gene mRNA expression signature (CIN70), which has been previously shown to correlate tightly with chromosomal instability, in 2 independent cohorts of IDH-mutant astrocytomas (total n = 241), IDH-wildtype astrocytomas (n = 228), and oligodendrogliomas (n = 128). Our results show that CIN70 expression levels correlate with total CNV, as well as higher grade, progression-free survival, and overall survival in both IDH-mutant and IDH-wildtype astrocytomas. In oligodendrogliomas, these mRNA signatures correlate with total CNV but not consistently with clinical outcome. These data suggest that chromosomal instability is an underlying factor in aggressive behavior and progression of a subset of diffuse astrocytomas. In addition, chromosomal instability may in part explain the poor response of diffuse gliomas to treatment and may serve as a future therapeutic target.
PMID: 33755138
ISSN: 1554-6578
CID: 4822572
Molecular Analysis of Encapsulated Papillary Carcinoma of the Breast with and without Invasion
Schwartz, Christopher J; Boroujeni, Amir Momeni; Khodadai-Jamayran, Alireza; Heguy, Adriana; Snuderl, Matija; Jour, George; Cotzia, Paolo; Darvishian, Farbod
Encapsulated papillary carcinomas (EPC) of the breast is a unique variant of papillary carcinoma confined to a cystic space with absent or attenuated myoepithelial cell layer. Although staged as an in-situ lesion, it can be associated with invasive ductal carcinoma (IDC). We sought to compare the genomic characteristics of pure EPC and EPC with associated invasive carcinoma (EPCi) at the genomic level. All cases of EPCi harbored recurrent hotspot mutations in PIK3CA. PIK3CA, KMT2A and CREBBP deleterious somatic events were found across both tumor groups, irrespective of invasion status. At the whole transcriptomic level, EPCi cases displayed remarkably similar mRNA profiles when compared to EPC. When EPCi cases were compared with their corresponding IDC, despite significant overlap, we identified differential gene expression in 39 genes with enrichment of multiple pathways including extracellular matrix regulation, cell adhesion and collagen fibril organization. Despite morphologic, genotypic and transcriptomic overlap between pure EPC and EPCi, the latter tumors are likely advanced lesions with PIK3CA activating mutations and enrichment of stromal-related genes implicated in the switch to IDC.
PMID: 33667422
ISSN: 1532-8392
CID: 4801982
YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas
Schieffer, Kathleen M; Agarwal, Vibhuti; LaHaye, Stephanie; Miller, Katherine E; Koboldt, Daniel C; Lichtenberg, Tara; Leraas, Kristen; Brennan, Patrick; Kelly, Benjamin J; Crist, Erin; Rusin, Jerome; Finlay, Jonathan L; Osorio, Diana S; Sribnick, Eric A; Leonard, Jeffrey R; Feldman, Alexander; Orr, Brent A; Serrano, Jonathan; Vasudevaraja, Varshini; Snuderl, Matija; White, Peter; Magrini, Vincent; Wilson, Richard K; Mardis, Elaine R; Boué, Daniel R; Cottrell, Catherine E
Meningiomas are a central nervous system tumor primarily afflicting adults, with <1% of cases diagnosed during childhood or adolescence. Somatic variation in NF2 may be found in ∼50% of meningiomas, with other genetic drivers (eg, SMO, AKT1, TRAF7) contributing to NF2 wild-type tumors. NF2 is an upstream negative regulator of YAP signaling and loss of the NF2 protein product, Merlin, results in YAP overexpression and target gene transcription. This mechanism of dysregulation is described in NF2-driven meningiomas, but further work is necessary to understand the NF2-independent mechanism of tumorigenesis. Amid our institutional patient-centric comprehensive molecular profiling study, we identified an individual with meningioma harboring a YAP1-FAM118B fusion, previously reported only in supratentorial ependymoma. The tumor histopathology was remarkable, characterized by prominent islands of calcifying fibrous nodules within an overall collagen-rich matrix. To gain insight into this finding, we subsequently evaluated the genetic landscape of 11 additional pediatric and adolescent/young adulthood meningioma patients within the Children's Brain Tumor Tissue Consortium. A second individual harboring a YAP1-FAM118B gene fusion was identified within this database. Transcriptomic profiling suggested that YAP1-fusion meningiomas are biologically distinct from NF2-driven meningiomas. Similar to other meningiomas, however, YAP1-fusion meningiomas demonstrated overexpression of EGFR and MET. DNA methylation profiling further distinguished YAP1-fusion meningiomas from those observed in ependymomas. In summary, we expand the genetic spectrum of somatic alteration associated with NF2 wild-type meningioma to include the YAP1-FAM118B fusion and provide support for aberrant signaling pathways potentially targetable by therapeutic intervention.
PMID: 33074854
ISSN: 1532-0979
CID: 4641982
NTRK2 Fusion driven pediatric glioblastoma: Identification of oncogenic Drivers via integrative Genome and transcriptome profiling [Case Report]
Britton, Heidi M; Levine, Adrian B; Shen, Yaoqing; Mungall, Karen; Serrano, Jonathan; Snuderl, Matija; Pleasance, Erin; Jones, Steven J M; Laskin, Janessa; Marra, Marco A; Rassekh, Shahrad R; Deyell, Rebecca; Yip, Stephen; Cheng, Sylvia; Dunham, Chris
This is the first report of a NACC2-NTRK2 fusion in a histological glioblastoma. Oncogenomic analysis revealed this actionable fusion oncogene in a pediatric cerebellar glioblastoma, which would not have been identified through routine diagnostics, demonstrating the value of clinical genome profiling in cancer care.
PMCID:7981675
PMID: 33768871
ISSN: 2050-0904
CID: 4822992
Molecular classification and deconvolution of the immune microenvironment in glioblastoma
Snuderl, Matija
PMID: 33395481
ISSN: 1523-5866
CID: 4738602
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1
Sievers, Philipp; Sill, Martin; Blume, Christina; Tauziede-Espariat, Arnault; Schrimpf, Daniel; Stichel, Damian; Reuss, David E; Dogan, Helin; Hartmann, Christian; Mawrin, Christian; Hasselblatt, Martin; Stummer, Walter; Schick, Uta; Hench, Jürgen; Frank, Stephan; Ketter, Ralf; Schweizer, Leonille; Schittenhelm, Jens; Puget, Stéphanie; Brandner, Sebastian; Jaunmuktane, Zane; Küsters, Benno; Abdullaev, Zied; Pekmezci, Melike; Snuderl, Matija; Ratliff, Miriam; Herold-Mende, Christel; Unterberg, Andreas; Aldape, Kenneth; Ellison, David W; Wesseling, Pieter; Reifenberger, Guido; Wick, Wolfgang; Perry, Arie; Varlet, Pascale; Pfister, Stefan M; Jones, David T W; von Deimling, Andreas; Sahm, Felix
Clear cell meningioma represents an uncommon variant of meningioma that typically affects children and young adults. Although an enrichment of loss-of-function mutations in the SMARCE1 gene has been reported for this subtype, comprehensive molecular investigations are lacking. Here we describe a molecularly distinct subset of tumors (n = 31), initially identified through genome-wide DNA methylation screening among a cohort of 3093 meningiomas, of which most were diagnosed histologically as clear cell meningioma. This cohort was further supplemented by an additional 11 histologically diagnosed clear cell meningiomas for analysis (n = 42). Targeted DNA sequencing revealed SMARCE1 mutations in 33/34 analyzed samples, accompanied by a nuclear loss of expression determined via immunohistochemistry and a decreased SMARCE1 transcript expression in the tumor cells. Analysis of time to progression or recurrence of patients within the clear cell meningioma group (n = 14) in comparison to those with meningioma WHO grade 2 (n = 220) revealed a similar outcome and support the assignment of WHO grade 2 to these tumors. Our findings indicate the existence of a highly distinct epigenetic signature of clear cell meningiomas, separate from all other variants of meningiomas, with recurrent mutations in the SMARCE1 gene. This suggests that these tumors may arise from a different precursor cell population than the broad spectrum of the other meningioma subtypes.
PMID: 33319313
ISSN: 1432-0533
CID: 4717752
LMNA-NTRK1 Rearranged Mesenchymal Tumor (Lipofibromatosis-like Neural Tumor) Mimicking Pigmented Dermatofibrosarcoma Protuberans [Case Report]
Panse, Gauri; Reisenbichler, Emily; Snuderl, Matija; Wang, Wei-Lien; Laskin, William; Jour, George
We present the case of a 31-year-old female with 1.5 cm pigmented nodule on the scalp. Histopathological examination revealed a proliferation of relatively bland spindle cells and pigmented dendritic cells with interspersed lymphoid follicles diffusely infiltrating the adipose tissue. The microscopic differential diagnosis included pigmented dermatofibrosarcoma protuberans (DFSP). The spindle cells showed S-100 and CD34 labeling but were negative for SOX-10. Immunohistochemical stain for pan-TRK was positive, while fluorescence in-situ hybridization for PDGFB gene rearrangement was negative. Targeted RNA sequencing revealed a LMNA-NTRK1(Exon2/Exon10) fusion. This molecular result coupled with the histopathologic findings and immunohistochemical profile supported the diagnosis of the recently characterized NTRK-rearranged spindle cell neoplasm termed "lipofibromatosis-like neural tumor (LPF-NT)". These neoplasms typically occur in superficial soft tissue and are characterized by a distinctive immunoprofile (CD34+, S-100+, SOX10-). Histopathological differential diagnosis for LPF-NT tumors includes lipofibromatosis, DFSP, low-grade malignant peripheral nerve sheath tumor and spindle cell/desmoplastic melanoma. The pigmented dendritic cells reminiscent of pigmented DFSP and lymphoid follicles noted in our case have not been previously reported in LPF-NT, thus expanding the morphologic spectrum of this entity. LMNA-NTRK1 fusion serves both as a diagnostic and therapeutic biomarker, as cases with advanced disease may be amenable to targeted therapy using tyrosine kinase inhibitors. This article is protected by copyright. All rights reserved.
PMID: 32519338
ISSN: 1600-0560
CID: 4478342
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR
Sievers, Philipp; Sill, Martin; Schrimpf, Daniel; Stichel, Damian; Reuss, David E; Sturm, Dominik; Hench, Jürgen; Frank, Stephan; Krskova, Lenka; Vicha, Ales; Zapotocky, Michal; Bison, Brigitte; Castel, David; Grill, Jacques; Debily, Marie-Anne; Harter, Patrick N; Snuderl, Matija; Kramm, Christof M; Reifenberger, Guido; Korshunov, Andrey; Jabado, Nada; Wesseling, Pieter; Wick, Wolfgang; Solomon, David A; Perry, Arie; Jacques, Thomas S; Jones, Chris; Witt, Olaf; Pfister, Stefan M; von Deimling, Andreas; Jones, David T W; Sahm, Felix
BACKGROUND:Malignant astrocytic gliomas in children show a remarkable biological and clinical diversity. Small in-frame insertions or missense mutations in the EGFR gene have recently been identified in a distinct subset of pediatric-type bithalamic gliomas with a unique DNA methylation pattern. METHODS:Here, we investigated an epigenetically homogeneous cohort of malignant gliomas (n=58) distinct from other subtypes and enriched for pediatric cases and thalamic location, in comparison with this recently identified subtype of pediatric bithalamic gliomas. RESULTS:EGFR gene amplification was detected in 16/58 (27%) tumors, and missense mutations or small in-frame insertions in EGFR were found in 20/30 tumors with available sequencing data (67%; five of them co-occurring with EGFR amplification). Additionally, eight of the 30 tumors (27%) harbored an H3.1 or H3.3 K27M mutation (six of them with a concomitant EGFR alteration). All tumors tested showed loss of H3K27me3 staining, with evidence of EZHIP overexpression in the H3 wildtype cases. Although some tumors indeed showed a bithalamic growth pattern, a significant proportion of tumors occurred in the unilateral thalamus or in other (predominantly midline) locations. CONCLUSIONS:Our findings present a distinct molecular class of pediatric-type malignant gliomas largely overlapping with the recently reported bithalamic gliomas characterized by EGFR alteration, but additionally showing a broader spectrum of EGFR alterations and tumor localization. Global H3K27me3 loss in this group appears to be mediated by either H3 K27 mutation or EZHIP overexpression. EGFR inhibition may represent a potential therapeutic strategy in these highly aggressive gliomas.
PMID: 33130881
ISSN: 1523-5866
CID: 4663842
Sarcoma classification by DNA methylation profiling
Koelsche, Christian; Schrimpf, Daniel; Stichel, Damian; Sill, Martin; Sahm, Felix; Reuss, David E; Blattner, Mirjam; Worst, Barbara; Heilig, Christoph E; Beck, Katja; Horak, Peter; Kreutzfeldt, Simon; Paff, Elke; Stark, Sebastian; Johann, Pascal; Selt, Florian; Ecker, Jonas; Sturm, Dominik; Pajtler, Kristian W; Reinhardt, Annekathrin; Wefers, Annika K; Sievers, Philipp; Ebrahimi, Azadeh; Suwala, Abigail; Fernández-Klett, Francisco; Casalini, Belén; Korshunov, Andrey; Hovestadt, Volker; Kommoss, Felix K F; Kriegsmann, Mark; Schick, Matthias; Bewerunge-Hudler, Melanie; Milde, Till; Witt, Olaf; Kulozik, Andreas E; Kool, Marcel; Romero-Pérez, Laura; Grünewald, Thomas G P; Kirchner, Thomas; Wick, Wolfgang; Platten, Michael; Unterberg, Andreas; Uhl, Matthias; Abdollahi, Amir; Debus, Jürgen; Lehner, Burkhard; Thomas, Christian; Hasselblatt, Martin; Paulus, Werner; Hartmann, Christian; Staszewski, Ori; Prinz, Marco; Hench, Jürgen; Frank, Stephan; Versleijen-Jonkers, Yvonne M H; Weidema, Marije E; Mentzel, Thomas; Griewank, Klaus; de Ãlava, Enrique; MartÃn, Juan DÃaz; Gastearena, Miguel A Idoate; Chang, Kenneth Tou-En; Low, Sharon Yin Yee; Cuevas-Bourdier, Adrian; Mittelbronn, Michel; Mynarek, Martin; Rutkowski, Stefan; Schüller, Ulrich; Mautner, Viktor F; Schittenhelm, Jens; Serrano, Jonathan; Snuderl, Matija; Büttner, Reinhard; Klingebiel, Thomas; Buslei, Rolf; Gessler, Manfred; Wesseling, Pieter; Dinjens, Winand N M; Brandner, Sebastian; Jaunmuktane, Zane; Lyskjær, Iben; Schirmacher, Peter; Stenzinger, Albrecht; Brors, Benedikt; Glimm, Hanno; Heining, Christoph; Tirado, Oscar M; Sáinz-Jaspeado, Miguel; Mora, Jaume; Alonso, Javier; Del Muro, Xavier Garcia; Moran, Sebastian; Esteller, Manel; Benhamida, Jamal K; Ladanyi, Marc; Wardelmann, Eva; Antonescu, Cristina; Flanagan, Adrienne; Dirksen, Uta; Hohenberger, Peter; Baumhoer, Daniel; Hartmann, Wolfgang; Vokuhl, Christian; Flucke, Uta; Petersen, Iver; Mechtersheimer, Gunhild; Capper, David; Jones, David T W; Fröhling, Stefan; Pfister, Stefan M; von Deimling, Andreas
Sarcomas are malignant soft tissue and bone tumours affecting adults, adolescents and children. They represent a morphologically heterogeneous class of tumours and some entities lack defining histopathological features. Therefore, the diagnosis of sarcomas is burdened with a high inter-observer variability and misclassification rate. Here, we demonstrate classification of soft tissue and bone tumours using a machine learning classifier algorithm based on array-generated DNA methylation data. This sarcoma classifier is trained using a dataset of 1077 methylation profiles from comprehensively pre-characterized cases comprising 62 tumour methylation classes constituting a broad range of soft tissue and bone sarcoma subtypes across the entire age spectrum. The performance is validated in a cohort of 428 sarcomatous tumours, of which 322 cases were classified by the sarcoma classifier. Our results demonstrate the potential of the DNA methylation-based sarcoma classification for research and future diagnostic applications.
PMID: 33479225
ISSN: 2041-1723
CID: 4760962
Somatic Focal Copy Number Gains of Noncoding Regions of Receptor Tyrosine Kinase Genes in Treatment-Resistant Epilepsy
Vasudevaraja, Varshini; Rodriguez, Javier Hernaez; Pelorosso, Cristiana; Zhu, Kaicen; Buccoliero, Anna Maria; Onozato, Maristela; Mohamed, Hussein; Serrano, Jonathan; Tredwin, Lily; Garonzi, Marianna; Forcato, Claudio; Zeck, Briana; Ramaswami, Sitharam; Stafford, James; Faustin, Arline; Friedman, Daniel; Hidalgo, Eveline Teresa; Zagzag, David; Skok, Jane; Heguy, Adriana; Chiriboga, Luis; Conti, Valerio; Guerrini, Renzo; Iafrate, A John; Devinsky, Orrin; Tsirigos, Aristotelis; Golfinos, John G; Snuderl, Matija
Epilepsy is a heterogenous group of disorders defined by recurrent seizure activity due to abnormal synchronized activity of neurons. A growing number of epilepsy cases are believed to be caused by genetic factors and copy number variants (CNV) contribute to up to 5% of epilepsy cases. However, CNVs in epilepsy are usually large deletions or duplications involving multiple neurodevelopmental genes. In patients who underwent seizure focus resection for treatment-resistant epilepsy, whole genome DNA methylation profiling identified 3 main clusters of which one showed strong association with receptor tyrosine kinase (RTK) genes. We identified focal copy number gains involving epidermal growth factor receptor (EGFR) and PDGFRA loci. The dysplastic neurons of cases with amplifications showed marked overexpression of EGFR and PDGFRA, while glial and endothelial cells were negative. Targeted sequencing of regulatory regions and DNA methylation analysis revealed that only enhancer regions of EGFR and gene promoter of PDGFRA were amplified, while coding regions did not show copy number abnormalities or somatic mutations. Somatic focal copy number gains of noncoding regulatory represent a previously unrecognized genetic driver in epilepsy and a mechanism of abnormal activation of RTK genes. Upregulated RTKs provide a potential avenue for therapy in seizure disorders.
PMID: 33274363
ISSN: 1554-6578
CID: 4694512